加强气候信息披露 沛嘉医疗ESG治理升级
Zhong Guo Zheng Quan Bao·2025-06-22 20:25

Core Viewpoint - The company, Peijia Medical, emphasizes the importance of a robust sustainable development management system as a foundation for high-quality growth, as highlighted in its 2024 ESG report [1]. Group 1: ESG Reporting and Governance - Peijia Medical has released five ESG reports since its listing in May 2020, with the 2024 report enhancing climate-related disclosures and improving human resources and supplier management practices [2]. - The company has established a three-tier governance structure for ESG, involving the board of directors, an ESG management office, and an ESG working group to oversee sustainable development initiatives [3]. - The company has identified 20 core ESG issues that significantly impact stakeholders, with a focus on product quality, compliance, employee welfare, and innovation [3]. Group 2: Environmental Initiatives - Peijia Medical has implemented various energy-saving projects, including a steam energy-saving transformation project expected to save between 800,000 to 1,000,000 yuan annually [4]. - The company has successfully launched a rainwater recycling system that saves approximately 70,000 yuan in water costs each year, contributing to reduced water resource consumption [5]. - The company is actively promoting green production practices among suppliers, requiring them to adopt comprehensive environmental policies and prioritize the use of eco-friendly materials [5]. Group 3: Product Development and Accessibility - Peijia Medical has made significant advancements in its product lines, with 17 products approved in the neuro-interventional field and over 3,400 units of TAVR systems implanted in 2024 [6]. - The company is developing new products to address unmet clinical needs in valve treatment, with plans for several products to be approved and launched between late 2024 and 2026 [6]. - Peijia Medical is committed to enhancing product accessibility by participating in local medical insurance payment and centralized procurement initiatives to reduce patient costs [6].